INTENSITY THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.74 USD | -0.42% |
|
-3.66% | -44.69% |
Valuation
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Capitalization 1 | 117.5 | 65.27 |
| Enterprise Value (EV) 1 | 117.5 | 65.27 |
| P/E ratio | -6.21 x | -3.4 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | - |
| Nbr of stocks (in thousands) | 13,709 | 13,712 |
| Reference price 2 | 8.570 | 4.760 |
| Announcement Date | 3/14/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA | - | - | - |
| EBIT 1 | - | -8.319 | -19.74 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | - | -10.54 | -19.3 |
| Net income 1 | -7.582 | -11.86 | -19.3 |
| Net margin | - | - | - |
| EPS 2 | -2.220 | -1.380 | -1.400 |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 5/18/23 | 3/14/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -1.222 | -2.491 | -3.353 | - | -4.8 | -5 | -5.2 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.701 | -2.33 | -3.171 | - | -4.68 | -4.9 | -5.12 |
| Net income 1 | -3.701 | -2.33 | -4.495 | - | -4.68 | -4.9 | -5.12 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -1.050 | -0.1700 | -0.1200 | -0.3400 | -0.3400 | -0.3600 | -0.3700 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/14/23 | 11/13/23 | 3/14/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Debt | - | - | - |
| Net Cash position | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share | - | - | - |
| Cash Flow per Share 2 | - | -0.8400 | -0.2500 |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | 5/18/23 | 3/14/24 | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.74
USD
Average target price
12
USD
Spread / Average Target
+153.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.69% | 65.27M | |
| +16.71% | 44.63B | |
| +42.66% | 40.46B | |
| -7.92% | 38.07B | |
| +33.09% | 32.27B | |
| -7.10% | 27.3B | |
| +14.46% | 26.53B | |
| +46.73% | 14.06B | |
| +34.07% | 12.54B | |
| -7.61% | 11.28B |
- Stock Market
- Equities
- INTS Stock
- Financials Intensity Therapeutics, Inc.
